New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity

Eli Lilly reported 52-week results from the Phase 3b TOGETHER-PsO (n=274) and TOGETHER-PsA (n=271) showing that concomitant Taltz (ixekizumab) + Zepbound (tirzepatide) benefits persist or improve through one year versus Taltz alone, with no new safety concerns. In TOGETHER-PsO, the Week-52 primary endpoint (PASI 100 plus ≥10% weight loss) was achieved by 30.6% vs 4.4% on Taltz alone, and complete skin clearance (PASI 100) was maintained at 40.5% vs 29.1%. In TOGETHER-PsA, the primary endpoint (ACR50 plus ≥10% weight loss) was 39.2% vs 1.7%, while ACR50 rose to 43.7% vs 15.7%; systemic inflammation (hsCRP) and multiple metabolic measures (BMI, BP, glucose, HbA1c, triglycerides, cholesterol) were sustained or further improved.

Analysis

This is incrementally positive for LLY, but the market should treat it as a narrative upgrade more than an earnings upgrade. The real mechanism is not the trial itself; it is whether dermatology/rheumatology becomes a new specialty channel for tirzepatide, extending the obesity franchise beyond the usual endocrinology/PCP funnel and reinforcing LLY’s premium multiple versus NVO. The read-through to competitors is more subtle: if obesity is increasingly viewed as a modifier of biologic response, pure-play inflammatory assets without metabolic benefit could face a mild valuation headwind over time.

Near term, the stock reaction should fade unless management uses this to expand the obesity TAM or provides payer/launch specifics. Over the next 1-3 months, the key catalyst is presentation/publication quality and whether KOLs start discussing combination therapy as a practical treatment pathway rather than an academic curiosity. The largest constraint is reimbursement: two branded injectables create a higher total cost of care, so payers can easily neutralize clinical enthusiasm with step edits, prior auth, or narrow coverage.

The contrarian view is that this may be scientifically interesting but commercially narrow. The payer horizon for psoriasis/PsA is shorter than the structural benefit horizon Lilly is implicitly advertising, and adherence may suffer once GI tolerability and injection burden are combined. If claims data do not show faster tirzepatide uptake in derm/rheum over the next 2-3 quarters, or if management stays silent on commercial translation, this should be treated as a sentiment event rather than a durable franchise expansion.

Key Decisions for Investors

• Buy LLY on any post-event weakness over the next 1-2 sessions; use this as a small add to a core position, with the thesis that the specialty-prescriber channel can modestly expand tirzepatide demand over 6-18 months. Exit/reduce if management later signals no reimbursement pathway or if follow-up publication is less convincing.
• Pair trade: long LLY / short NVO for 1-3 months as a relative-value expression on incretin leadership. The setup is that Lilly keeps widening the moat around non-diabetes use cases, while the market underappreciates how much of GLP-1 durability comes from channel expansion rather than just obesity penetration.
• Do not chase AMGN/ABBV/JNJ on this headline; use them only as watchlist names for any evidence that obesity-linked prescribing shifts into psoriasis/PsA workflows. No trade until prescription or formulary data confirm spillover.
• If LLY implied volatility softens after the initial move, consider a 3-6 month call spread rather than outright stock to express the optionality around congress/paper catalysts with defined downside.